- Poster presentation
- Open access
- Published:
Fluorinated groups mediate the immunomodulatory effects of volatile anesthetics in acute pulmonary inflammation
Critical Care volume 15, Article number: P419 (2011)
Introduction
Volatile anaesthetics are known as immunomodulatory substances in inflammatory as well as in ischemia/reperfusion processes [1, 2]. We investigated in a model of acute pulmonary inflammation whether these immunomodulatory effects arise from the ether basic structure or from characteristics in their halogenation.
Methods
Inflammatory response in pulmonary epithelial and endo-thelial cells as well as in neutrophils after co-exposure to endotoxin and sevoflurane, diethyl-ether or various water-soluble molecules carrying trifluorinated carbon groups (CF3) was evaluated. Expression of monocyte chemotactic protein-1 and cytokine-induced neutrophil chemoattractant protein-1, IL-6, and IL-8 as a measure of inflammatory activity were analyzed by ELISA. Chemotactic activity of supernatants regarding neutrophil recruitment was assessed. Flow cytometric analysis of neutrophil activation was performed measuring CD11b and CD62L expression. Viability was observed using fluorescence DNA quantitation. Cytotoxicity was evaluated by measuring lactate dehydrogenase in supernatants.
Results
Expression of inflammatory mediators to lipopolysaccharide stimulation in epithelial and endothelial cells was dose-dependently decreased upon exposure to sevoflurane and other molecules with CF3 groups. This was not observed for diethyl-ether or structure-similar nonfluorinated molecules. In neutrophils, chemotactic activity as well as expression of surface CD11b and CD62L was decreased by molecules carrying CF3 groups. Cytotoxicity could be excluded.
Conclusions
These findings show that the immunomodulatory effects are not limited to volatile anesthetics, but are associated with a much broader class of CF3 group-containing molecules. The immunomodulatory effects could now be provided in a hydrophilic, injectable formulation for the future treatment of patients suffering from acute pulmonary inflammation in environments not suitable for volatile anesthetics.
References
Ross S, et al.: Br J Anaesth. 1999, 82: 622-632.
Voigtsberger S, et al.: Anesthesiology. 2009, 111: 1238-1248.
Author information
Authors and Affiliations
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Urner, M., Herrmann, I., Müller-Edenborn, B. et al. Fluorinated groups mediate the immunomodulatory effects of volatile anesthetics in acute pulmonary inflammation. Crit Care 15 (Suppl 1), P419 (2011). https://doi.org/10.1186/cc9839
Published:
DOI: https://doi.org/10.1186/cc9839